# 1 The kinetic of SARS-CoV-2 antibody (Ab) decline determines the threshold for Ab persistence up to 2 one year

- 3
- 4 Erika Garner-Spitzer<sup>1</sup>, Angelika Wagner<sup>1</sup>, Michael Kundi<sup>2</sup>, Hannes Stockinger<sup>3</sup>, Anna Repic<sup>3</sup>, Anna-
- 5 Margarita Schoetta<sup>3</sup>, Venugopal Gudipati<sup>3</sup>, Johannes B. Huppa<sup>3</sup>, Renate Kunert<sup>4</sup>, Patrick Mayrhofer<sup>4</sup>,
- 6 Thomas R. Kreil<sup>5</sup>, Maria R. Farcet<sup>5</sup>, Eva Hoeltl<sup>6</sup>, Ursula Wiedermann<sup>1\*</sup>
- 7
- 8 1 Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and
- 9 Immunology, Medical University of Vienna, Vienna, Austria
- 10 2 Center for Public Health, Medical University of Vienna, Vienna, Austria
- 11 3 Institute for Hygiene and Applied Immunology, Centre for Pathophysiology, Infectiology and
- 12 Immunology, Medical University of Vienna, Vienna, Austria
- 13 4 Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna
- 14 5 Global Pathogen Safety, Baxter AG, a Takeda company, Vienna, Austria
- 15 6 Health Center Erste Bank, Erste Bank, Vienna, Austria
- 16
- 17 \*<u>Correspondence</u>:
- 18 Univ. Prof. Ursula Wiedermann, MD, PhD
- 19 Institute of Specific Prophylaxis and Tropical Medicine
- 20 Centre for Pathophysiology, Infectiology and Immunology
- 21 Medical University of Vienna
- 22 Kinderspitalgasse 15, Vienna A-1090, Austria
- 23 Email: <u>ursula.wiedermann@meduniwien.ac.at</u>
- 24

25 Abstract: Twelve subjects with positive SARS-CoV-2 neutralization test (NT) titers (>1:10) identified in 26 a seroprevalence study with 1655 working adults were followed up for one year. Here we report that 27 7 of these 12 individuals (58%) still had NT titers ≥1:50, S1-specific IgG concentrations ≥50 BAU/ml 28 and  $\geq$ 26% ACE2 receptor binding inhibition, measured with surrogate virus NT one year after mild 29 COVID infection. Furthermore, NT 50 titers >1:10 and S1-specific IqG levels >60 BAU/ml present at 30 three months post-infection persisted at detectable levels for 1 year and correlated with circulating 31 S1-specific memory B-cells. Vaccine-induced SARS-CoV2 immune responses decline at similar rates as 32 those after infection; thus the describes threshold of 60 BAU/ml at three months post infection might 33 also be relevant for assessment of Ab persistence after vaccination.

34

35 We recently reported in a longitudinal seroprevalence study conducted in a cohort of working adults 36 (n=1655) that neutralizing SARS-CoV-2 RBD-specific antibodies (Abs) persist for at least six months 37 independent of symptom severity (1). This study cohort was followed up to one year and twelve 38 selected subjects with positive neutralization test (NT) titers (>1:10) after infection were analyzed in 39 detail to assess their long-term Ab persistence, T cell reactivity and memory B cells over the course of 40 one year. SARS-CoV-2-specific Abs were evaluated guantitatively with neutralization test (NT 50 1:x) 41 and S1 IgG ELISA (BAU/mI), and semi-quantitatively with surrogate-virus neutralization test (sVNT) (% 42 inhibition), RBD Ab ELISA (ratio) and NCP IgG ELISA (ratio) in serum samples obtained after mild 43 COVID infection and 3 months, 6 months and one year thereafter. On cellular level, S1-specific B 44 memory cells were quantified by flow-cytometry and cytokines were measured in culture

supernatants of S1-protein re-stimulated PBMC (see Supporting Information). The ethics committee
 of the Medical University of Vienna approved this monocentric study (EK 1438/2020, EK 1746/2020).

- 47
- 48 Results:

Our results show that 7 of 12 subjects (58 %) still had NT titers  $\geq$ 1:50 (positive >1:10), S1-specific lgG concentrations  $\geq$ 50 BAU/ml (seropositive >35.2 BAU/ml) and  $\geq$ 26% binding inhibition with sVNT (cutoff 20%) after one year (Fig.1 A-C). In all subjects RBD-specific Abs remained above the positive cutoff (ratio >1.1), while NCP-specific lgG declined below negative cut-off (ratio <0.8) between 6 months and one year (Fig.1 D, E).



medRxiv preprint doi: https://doi.org/10.1101/2021.09.20.21263172; this version posted September 27, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 1 A-F: Kinetics of SARS-CoV-2- specific Abs measured with different assays. A) NT\_50 titers 1:x, B) S1 specific IgG in BAU/ml, C) % inhibition in sVNT, D) RBD-specific Ab ratios and E) NCP-specific IgG ratios post infection and 3 months, 6 months and 1 year thereafter; red lines indicate positive cut-off values, negative cut off for NCP IgG. F) GM & 95% Cl of NT\_50 titers, Mean & 95% Cl of S1-specific IgG and % inhibition in sVNT.
 <u>Abbr.</u>: BAU, binding antibody units; Cl, confidence interval; GM, Geometric Mean; NT\_50, reciprocal sample
 dilution resulting in 50% virus neutralization; NCP, nucleo capside protein; RBD, SARS-CoV-2 receptor binding
 domain; S1, SARS-CoV-2 Spike protein 1; sVNT, surrogate-virus neutralization test.

In order to define a threshold for the persistence of SARS-CoV-2-specific Abs, we correlated the
results from three months and one year post-infection. Importantly, NT\_50 titers >1:10 at three
months after infection remained stable for one year (r=0.861, p=0.0006; Fig.2 A). Regarding S1specific IgGs, levels >60 BAU/ml also showed robust maintenance up to one year (r=0.846, p=0.0009;
Fig.2 B).



103Figure 2 A, B: Relationship between log transformed Ab concentrations measured 3 months and 1 year post104infection for A) NT\_50 titers 1:x ( $r_s$  =0.861, p=0.0006), and B) S1-specific IgG in BAU/ml ( $r_s$  =0.846, p=0.0009).105Grey lines indicate negative cut-off, red lines indicate potential thresholds for persistence after 3 months, and106green lines indicate retained Ab concentrations after 1 year.

107 The decline kinetics of infection-induced Abs (as also known for vaccine-induced Abs) are best 108 described by two-component models (2-5). The first component, starting after maximum Ab levels 109 are reached a few weeks after completed vaccination or resolved symptoms, is an initial fast decline. 110 The second component starts after a few months and is slowly declining (Fig. 1 F). We applied such a 111 model for the Abs measured with different assays, and observed a strong correlation of NT 50 titers 112 with S1-specific IgG and sVNT results for both the fast and slow decline component (NT 50, S1 IgG: 113 fast component: r=0.596, p=0.041; slow component: r=0.571, p=0.047; NT 50, sVNT: fast 114 component: r=0.700, p=0.011; slow component: r=0.691, p=0.013). Decline kinetics of NCP IgG ratios 115 were similar, while RBD-specific Ab ratios showed a different pattern with further increase up to 3 116 months in most subjects and then slight decline within one year.

117Investigating the persistence of SARS-CoV-2 immunity on cellular level, we observed a clear positive118correlation of NT\_50 titers, S1-specific IgG and circulating S1-specific memory B-cells one year after

119 infection. In contrast, S1-specifc IFN-y and IL-2 levels upon PBMC re-stimulation were higher in

120	subjects with low	wer Ab le	vels und f	fewer B	memory	cells,	which	did not	apply fo	or the	NCP-specific

121 cytokines (Table 1).

#### 122

Subject Nr.	age range /years	gender	BAU/ml (1y)	NT_50 1:x (1y)	B cells (% of lymphos )	B-memory cells (% of B cells)	% S1- S specific (I B memory (I		1- & NCP- pecifc L-2 pg/ml) vs. baseline		S1- & NCP- specifc IFN-y (pg/ml) vs. baseline		
5	45-50	m	54.9	66	7.1	25.2	0.30	34	31	2	17	15	7
8	50-55	m	59.1	66	6.7	18.5	0.41	27	10	1	13	10	6
10	30-35	m	103.0	85	11.8	14.1	0.79	8	12	0	12	12	6
12	50-55	f	55.4	55	8.1	12.9	0.36	56	18	1	43	13	3
naive	40-45	m			4.2	25.9	0.01						

123

Table 1: S1-specific IgG in BAU/ml, NT\_50 titers and respective percentages of B-cells, B memory cells and S1 specific B memory cells quantified by flow-cytometry for four COVID convalescent subjects and one SARS-CoV-2
 naïve control. S1- and NCP-specific IL-2 and IFN-y concentrations (in pg/ml vs. baseline) measured by Luminex
 technology in supernatants of re-stimulated PBMC cultures (24h).

128

## 129 **Discussion**:

130 In order to determine for how long SARS-CoV-2-specific Abs are actually maintained, this study shows 131 that measurement of Ab levels between 3 and 6 months after infection is crucial to assess Ab 132 persistence, which is determined by both maximal initial Ab concentrations and decline kinetics. Also 133 others report that SARS-CoV-2-specific immune parameters, e. g. RBD-specific Abs, their neutralizing 134 activity and RBD-specific memory B-cells remain rather stable between 6 and 12 months after 135 infection (6,7), but persistence has not been linked to NT\_50 and S1-specific IgG decline kinetics 136 and/or threshold.

137 We here propose S1-specific IgG concentrations of 60 BAU/ml three months post-infection as a 138 potential threshold to predict maintenance of neutralizing Ab levels for one year. S1-specific IgG (in 139 BAU) determined by ELISA are more accessible than NT assay results and might thus be more suitable 140 for routine measurements (8). We further show that the frequency of persisting S1-specifc B memory cells correlated with the level of maintained Abs in recovered subjects. A recent publication 141 142 described a clear correlation between post infection memory B cells and subsequent vaccine induced 143 antibody levels (9), indicating an immunological booster response originating from the previously 144 established memory B cells.

Ab-mediated virus neutralization is not the only mechanism of protection against SARS-CoV-2 infection and T-cell immunity in convalescent COVID-19 patients has been shown to maintain for 180 days despite varying kinetics of the neutralizing Ab responses (e.g. slow/rapid waning or persistence) (10). Our data indicate that also one year after infection Abs are not necessarily accompanied by antigen-specific T cell recall responses, as more S1-specific T-cell proliferation (IL-2) was present in subjects retaining lower Ab levels.

- 151 Taken together, our data suggest that a threshold of Ab levels can be identified three months after
- 152 (even) mild infection predicating persistence of SARS-CoV-2 specific Ab levels up to one year. Several
- mathematical models show that NT titers and S1 IgG binding Abs correlate with protective vaccine

155 (12). Thus, our identified threshold might be helpful in assessing protection after vaccination, in

- particular as long as no valid correlate of protection has been identified in vaccine trials.
- 157 158
- 159 Materials & Methods:
- 160 **Ab measurements**:

SARS-CoV-2 neutralization test (NT) assay was performed as previously described (13). Anti-SARS-CoV-2-QuantiVac-ELISA (IgG), SARS-CoV-2-NeutraLISA surrogate virus neutralization test (sVNT) and SARS-CoV-2 NCP-specific IgG ELISA, all obtained from Euroimmune®, Euroimmun Medizinische Labordiagnostik AG (Lübeck, Germany) were carried out according to the manufacturer's instructions. SARS-CoV-2 RBD-specific Abs were determined with commercial ELISA for total Abs (Beijing Wantai Biological Pharmacy Enterprise, Beijing, China) according to manufacturer's instructions.

For detailed information on SARS-CoV-2-specific Ab detection, quantification of S1-specific B
 memory cells, S1-specific re-stimulation of PBMC and cytokine measurements see Supplementary
 Information.

171

### 172 Author contributions:

UW, HS, AW, EH, TRK, and EGS designed research; EGS, AR, AS and MRF performed research; VG,
JBH, RK and PM contributed new analytic tools; EGS and MK analyzed data; and EGS, MK and UW
wrote the paper.

176

### 177 Acknowledgements:

We would like to thank Sylvia Rudolf and Clemens Burtscher, MD (both Health Center Erste Bank,
Erste Bank, Vienna, Austria), as well as Ines Zwazl (BSc), Maria Orola (MSc), Santino Posch, all
associated with the Institute of Specific Prophylaxis and Tropical Medicine, Medical University of
Vienna, and Vanessa Maurer (BSc), Tatjana Matschi (BSc), Karin Schoiswohl (BSc), Barbara Schaar
(BSc) and Andrea Wendl (BSc), all associated with the Institute for Hygiene and Applied Immunology,
Medical University of Vienna, for their excellent administrative and technical support.

SARS-CoV-2 was sourced via EVAg (supported by the European Community) and kindly provided by
Christian Drosten and Victor Corman (Charité Universitätsmedizin, Institute of Virology, Berlin,
Germany).

The study received funding from the Austrian Federal Ministry of Education, Science and Research
within the research framework in relation to the coronavirus disease 2019 pandemic (GZ 20200225
104).

190

### 191 <u>References</u>:

- Angelika Wagner AG, Johanna Ruff, Joanna Jasinska, Ute Scheikl, Ines Zwazl, Michael Kundi,
   Hannes Stockinger, Maria R. Farcet, Thomas R. Kreil, Eva Hoeltl & Ursula Wiedermann.
   Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently
- 195 of symptoms in adults. *Communications Medicine* 2021 doi https://doi.org/10.1038/s43856-196 021-00012-4.
- Wiedermann G, Kundi M, Ambrosch F, Safary A, D'Hondt E, Delem A. Inactivated hepatitis A
   vaccine: long-term antibody persistence. *Vaccine* 1997;15(6-7):612-5 doi 10.1016/s0264 410x(96)00242-3.
- Paulke-Korinek M, Kollaritsch H, Kundi M, Zwazl I, Seidl-Friedrich C, Jelinek T. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis. *Vaccine* 2015;**33**(30):3600-4 doi 10.1016/j.vaccine.2015.037.
- Van Damme P, Leroux-Roels G, Suryakiran P, Folschweiller N, Van Der Meeren O. Persistence
   of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine. *Human vaccines & immunotherapeutics* 2017;13(5):972-80 doi 10.1080/21645515.2016.1274473.
- Chappuis F, Farinelli T, Deckx H, Sarnecki M, Go O, Salzgeber Y, *et al.* Immunogenicity and
   estimation of antibody persistence following vaccination with an inactivated virosomal
   hepatitis A vaccine in adults: A 20-year follow-up study. *Vaccine* 2017;**35**(10):1448-54 doi
   10.1016/j.vaccine.2017.01.031.
- Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally
  enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 2021 doi
  10.1038/s41586-021-03696-9.
- Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling MJ, et al. Evolution of antibody
   responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. *EBioMedicine* 2021;**71**:103561 doi 10.1016/j.ebiom.2021.103561.
- 2168.Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nature217medicine 2021 doi 10.1038/s41591-021-01432-4.
- 2189.Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. Longitudinal219Analysis Reveals Distinct Antibody and Memory B Cell Responses in SARS-CoV2 Naive and220Recovered Individuals Following mRNA Vaccination. medRxiv : the preprint server for health221sciences 2021 doi 10.1101/2021.03.03.21252872.
- Chia WN, Zhu F, Ong SWX, Young BE, Fong SW, Le Bert N, et al. Dynamics of SARS-CoV-2
   neutralising antibody responses and duration of immunity: a longitudinal study. *The Lancet Microbe* 2021;2(6):e240-e9 doi 10.1016/S2666-5247(21)00025-2.
- 11. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing
  antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2
  infection. Nature medicine 2021 doi 10.1038/s41591-021-01377-8.
- 22812.Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence229for antibody as a protective correlate for COVID-19 vaccines. Vaccine 2021;39(32):4423-8 doi23010.1016/j.vaccine.2021.05.063.
- Schwaiger J, Karbiener M, Aberham C, Farcet MR, Kreil TR. No SARS-CoV-2 Neutralization by
   Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic.
   The Journal of infectious diseases 2020;222(12):1960-4 doi 10.1093/infdis/jiaa593.

234